Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going
- 24 June 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (7), 883-885
- https://doi.org/10.1093/ecco-jcc/jjaa028
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Risk for Herpes Zoster in Tofacitinib‐Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and GlucocorticoidsArthritis Care & Research, 2019
- Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experienceTherapeutic Advances in Gastroenterology, 2019
- Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative ColitisClinical Gastroenterology and Hepatology, 2018
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisClinical Gastroenterology and Hepatology, 2018
- Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysisAnnals of Gastroenterology, 2018
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant TherapyArthritis & Rheumatology, 2017
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2017
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementJournal of Crohn's and Colitis, 2017
- Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to SteroidsThe American Journal of Gastroenterology, 2016
- Systematic ReviewInflammatory Bowel Diseases, 2015